Bristol Myers reports two Phase 3 wins, but lung drug data confound

· Health · United States

Bristol Myers Squibb reported two Phase 3 successes on Monday, including for an experimental drug that recently ran into safety issues. A trial testing the lung disease program admilparant succeeded, and the company also reported a win for a RayzeBio drug. But only the lower of two tested doses of admilparant, for idiopathic pulmonary fibrosis, met the trial's main objective, adding to analyst questions about the therapy's prospects. Separately, Mirum Pharmaceuticals reported a late-stage win in ultra-rare liver diseases, with its ileal bile acid transporter inhibitor Livmarli significantly reducing cholestatic pruritus versus placebo.

Why it matters：Mixed dose-level results in fibrosis and rare-disease wins illustrate how uneven late-stage data are reshaping competition in respiratory and liver medicine.

Key points

  • Admilparant met the main goal only at the lower of two tested doses.
  • Bristol Myers also reported a Phase 3 win for a RayzeBio drug.
  • Mirum's Livmarli cut cholestatic pruritus versus placebo in rare liver diseases.

Sources (original reporting)

More stories from this day